Sustained release of tissue factor following thrombosis of lower limb trauma

Clinical and Applied Thrombosis/Hemostasis

Volumn 20, Issue 7, 2014, Pages 678-686

  Walenga, Jeanine M ^a   Kaiser, Phoebe C ^a   Prechel, M Margaret ^a   Hoppensteadt, Debra ^a   Jeske, Walter P ^a   Misselwitz, Frank ^b   Bacher, Peter ^c   Lassen, Michael R ^d   Fareed, Jawed ^a  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

^b BAYER PHARMA AG   (Germany)

^c ABBVIE INC   (United States)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Immobilization; Low molecular weight heparin; Lower limb; Reviparin; Tissue factor; Trauma; Venous thrombosis

Indexed keywords

HEPARIN; REVIPARIN; THROMBIN ANTITHROMBIN COMPLEX; THROMBOPLASTIN; ANTICOAGULANT AGENT; LOW MOLECULAR WEIGHT HEPARIN;

ACHILLES TENDON RUPTURE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; FRACTURE IMMOBILIZATION; HIGH RISK POPULATION; HUMAN; LEG INJURY; LEUKOCYTE ACTIVATION; MULTICENTER STUDY; PLASTER CAST; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBIN TIME; VENOUS THROMBOEMBOLISM; ACHILLES TENDON; BLOOD; FEMALE; FRACTURES, BONE; INJURIES; LEG; MALE; METABOLISM; MIDDLE AGED; PROSPECTIVE STUDY; TENDON INJURIES; TIME;

ACHILLES TENDON; ANTICOAGULANTS; DOUBLE-BLIND METHOD; FEMALE; FRACTURES, BONE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; LOWER EXTREMITY; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TENDON INJURIES; THROMBOPLASTIN; TIME FACTORS; VENOUS THROMBOEMBOLISM;

EID: 84927714456     PISSN: 10760296     EISSN: 19382723     Source Type: Journal    
DOI: 10.1177/1076029614545212     Document Type: Article

References (23)

1. Geerts WH, Code KI, Jay RM, Chen E, Szalai JP. A prospective study of venous thromboembolism after major trauma. N Eng J Med. 1994;331(24):1601-1606.
2. Rogers FB. Venous thromboembolism in trauma patients: a review. Surgery. 2001;130(1):1-12.
3. O'Malley KF, Ross SE. Pulmonary embolism in major trauma patients. J Trauma. 1990;30(6):748-750.
4. Kujath P, Spannagel U, Habscheid W. Incidence and prophylaxis of deep vein thrombosis in outpatients with injury of the lower limb. Haemostasis 1993;23(suppl 1):20-26.
5. Kock HJ, Schmit-Neuerburg KP, Hanke J, Rudofsky G, Hirche H. Thromboprophylaxis with low-molecular-weight heparin in outpatients with plaster-cast immobilisation of the leg. Lancet. 1995;346(8973):459-461.
6. Hjelmstedt A, Bergvall U. Phlebographic study of the incidence of thrombosis in the injured and uninjured limb in 55 cases of tibial fracture. Acta Chir Scand. 1968;134(3):229-234.
7. Abelseth G, Buckley RE, Pineo GE, Hull R, Rose MS. Incidence of deep-vein thrombosis in patients with fractures of the lower extremity distal to the hip. J Orthop Trauma. 1996; 10(4):230-235.
8. Jorgensen PS, Warming T, Hansen K, et al. Low molecular weight heparin (Innohep) as thromboprophylaxis in outpatients with a plaster cast: a venografic controlled study. Thromb Res. 2002;105(6):477-480.
9. Barrett JA, Baron JA, Beach ML. Mortality and pulmonary embolism after fracture in the elderly. Osteoporos Int. 2003; 14(11):889-894.
10. Nicolaides AN, Fareed J, Kakkar AK, et al. Prevention and treatment of venous thromboembolism. International Consensus Statement. Int Angiol. 2013;32(2):111-260.
11. Clagett GP, Anderson FA, Heit J, Levine MN, Brownell Wheeler H. Prevention of venous thromboembolism. Chest. 1995;108(4): 312S-334 S.
12. Nicolaides AN, Bergqvist D, Hull R, et al. Prevention of venous thromboembolism. International consensus statement. Int Angiol. 1997;16(1):3-38.
13. Lassen MR, Borris LC, Nakov RL. Use of the low-molecular weight heparin reviparin to prevent deep-vein thrombosis after leg injury requiring immobilization. N Engl J Med. 2002;347(10): 726-730.
14. Lang T, Secic M. Comparing groups. How to report statistics in medicine. Philadelphia, USA: American College of Physicians; 1997.
15. Nilsson-Helander K, Thomee R, Silbernagel KG, et al. The Achilles tendon Total Rupture Score (ATRS): development and validation. Am J Sports Med. 2007;35(3):421-426.
16. Samama CM, Lecoules N, Kierzek G, et al. Comparison of fondaparinux with low molecular weight heparin for venous thromboembolism prevention in patients requiring rigid or semi-rigid immobilization for isolated non-surgical below-knee injury. J Thromb Haemost. 2013;11(10):1833-1843.
17. Kaiser PC. Coagulation parameters and heparin-induced IgG antibodies in patients after lower limb trauma requiring immobilization treated with low molecular weight heparin, reviparin-a laboratory substudy of a placebo-controlled clinical trial. Dissertation for a medical doctoral degree, University of Heidelberg, Germany, 2003. Professor K. Andrassy, examiner.
18. Kaiser P, Prechel M, Hoppensteadt D, et al. Lower limb trauma is associated with a moderate risk of thrombosis caused by sustained release of tissue factor despite early functional mobilization. Thromb Haemost. 2003;1(suppl 1)(ISSN 1740-3340):P0940.
19. Kaiser P, Prechel M, Hoppensteadt D, et al. Reviparin normalizes tissue factor pathway activation in patients with lower limb immobilization and is not associated with heparin antibody production. Thromb Haemost. 2003;1(suppl 1)(ISSN 1740-3340):P2061.
20. Meissner MH, Chandler WL, Elliott JS. Venous thromboembolism in trauma: a local manifestation of systemic hypercoagulability? J Trauma. 2003;54(2):224-231.
21. Fedi S, Gori AM, Falciani M, et al. Procedure-dependence and tissue factor-independence of hypercoagulability during orthopedic surgery. Thromb Haemost. 1999;81(6):874-878.
22. Panes P, Matus V, Saez CG, Quiroga T, Pereira J, Mezzano D. Human platelets synthesize and express functional tissue factor. Blood. 2007;109(12):5242-5250.
23. Caprini J. Are you at risk for DVT? Caprini DVT Risk Score. Illinois State Medical Society. www.isms.org. Accessed February 15, 2013.